Status:
COMPLETED
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV dr...
Detailed Description
AMD11070 is an oral HIV-1 entry inhibitor that targets the CXCR4 receptor on T cells. AMD11070 has been shown safe and well-tolerated in Phase I clinical trials in HIV uninfected people. The goal of t...
Eligibility Criteria
Inclusion
- HIV-1 infected
- Have X4- or dual/mixed-tropic virus confirmed no more than 56 days prior to study entry
- HIV-1 viral load of 5,000 copies/ml or more within 60 days prior to study entry
- If female, willing to discontinue hormonal contraception 1 week prior to study entry
- Willing to use acceptable forms of contraception
Exclusion
- Antiretroviral treatment within 14 days prior to study entry
- Other prescription medications, herbal supplements, or aspirin within 7 days prior to study entry. Patients taking medication for prophylaxis for Pneumocystis carinii pneumonia (PCP) are not excluded. Patients taking medications approved by protocol officials are not excluded, provided they have been on a stable dose for at least 14 days prior to study entry.
- Nonsteroidal anti-inflammatory drugs (NSAIDS), over the counter medications, or other supplements (including multivitamins) within 1 day prior to study entry
- Heavy exercise within 24 hours before study entry evaluations are done
- Immunizations within 30 days prior to study entry
- Radiation therapy, cytotoxic chemotherapeutic agents, or immunomodulatory agents within 30 days prior to study entry
- Current use of some CYP substrates, inhibitors, or inducers. Use of CYP450 substrates is allowed, except for CYP2D6 and CYP2C8 substrates.
- Current use of P-gp inducers or inhibitors
- Allergy or sensitivity to study drug or its formulations
- Active infection or acute illness within 14 days prior to study entry, including HIV-associated opportunistic infections
- History of heart abnormalities. Patients with any repolarization delay (QTc interval of greater than 500 msec) or a history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia) are also excluded.
- Drug or alcohol abuse or dependence or other medical or psychological condition that, in the opinion of the investigator, would interfere with the study or put participants at undue risk
- Chronic diarrhea, defined as having more than 3 stools/day for more than 4 weeks prior to study entry
- Pregnant or breastfeeding
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00089466
Start Date
November 1 2004
End Date
January 1 2009
Last Update
November 9 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Therapeutics CRS
Birmingham, Alabama, United States, 35924-2050
2
The Ponce de Leon Ctr. CRS
Atlanta, Georgia, United States, 30308
3
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana, United States, 46202-5250